Background
Methods
Search criteria
Data extraction
Assessing risk of bias
Results
Database search and characteristics of included studies
Systemic biomarkers
Study | Design | No. of ALI/ARDS vs CPE | marker | Timing of measurement | Mean value ± SD/SEM or median (IQR or range) in ALI/ARDS | Mean value ± SD/SEM or median (IQR or range) in CPE | Unit |
p value | AUC | SD or 95% CI | Cutoff | For | Specificity (%) | Sensitivity (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Markers of cardiomyocyte stress | ||||||||||||||
Bajwa, 2013*** | Retrospective | 826 vs 87 | ST-2 | The day of enrollment | 534 (IQR325.0–724.9) | 43 (IQR26.4–78.6) | ng/mL | <0.0001 | 0.98 | n.d. (p <0.0001) | 142 | ALI/ARDS | 91 | 94 |
Komiya, 2011*** | Prospective | 53 vs 71 | BNP | Within 2 h after arriving | 202 (IQR95–439) | 691 (IQR416–1194) | pg/mL | <0.001 | 0.831 | 0.759–0.904 | 500 | CPE | 83.1 | 69 |
CRP | at ER | 119 (IQR62–165) | 8 (IQR2–42) | mg/L | <0.001 | 0.887 | 0.826–0.948 | 50 | ALI/ARDS | 69.8 | 59.2 | |||
BNP + CRP | n.d. | n.d. | n.d. | n.d. | 0.931 | 0.884–0.978 | n.d. | n.d. | n.d. | n.d. | ||||
Levitt, 2008** | Prospective | 33 vs 21 | BNP | Within 48 h of ICU adm. | 369 (IQR87–709) | 600 (IQR352–1300) | pg/mL | 0.04 | 0.67 | 0.52–0.81 | 100 | ALI/ARDS | 95.2 | 27.3 |
Karmpaliotis, 2007*** | Prospective | 51 vs 23 | BNP | Not stated | 325 (IQR82–767) | 1260 (IQR541–2020) | pg/mL | 0.0001 | 0.79 | n.d. | 200 | ALI/ARDS | 91 | 40 |
Rana, 2006*** | Retrospective + Prospective | 131 vs 73 | BNP | Median 3 h after diagnosis | 344 (IQR122–745) | 759 (IQR378–1320) | pg/mL | <0.001 | 0.71 | n.d. | 250 | ALI/ARDS | 90 | 40 |
Other circulating markers | ||||||||||||||
Lin Q, 2013*** | Prospective | 78 vs 28 | Plasma HBP | At enrollment | 17.15 (IQR11.95–24.07) | 9.50 (IQR7.98–12.18) | ng/mL | <0.001 | 0.851 | ±0.040 | 11.55 | ALI/ARDS | 78.2 | 75 |
Lin Q, 2012*** | Prospective | 87 vs 34 | Copeptin | At enrollment | 52.53 (IQR29.81–91.43) | 25.14 (IQR21.04–34.26) | pmol/L | <0.001 | 0.823 | ±0.038 | 40.11 | ALI/ARDS | 88.2 | 60.9 |
Arif, 2002* | Prospective | 11 vs 12 | Transferrin in plasma | Within 72 h of ICU adm. | 1.0 (range 0.5–1.5) | 2.1 (range 1.5–2.7) | g/L | <0.001 | 0.98 | n.d. | 1.5 | ARDS | 87 | 100 |
TP in plasma | 49 (range 41–59) | 63 (range 51–69) | g/L | <0.001 | 0.95 | n.d. | 59 | ARDS | 75 | 100 | ||||
Alb in plasma | 25 (range17–34) | 30 (range 25–43) | g/L | NS | 0.8 | n.d. | 24 | ARDS | 100 | 45 | ||||
Pulmonary leak index | 32.3 (range23.0–54.4) | 10.1 (range 4.4–16.2) | X10^-3/m | <0.001 | 1 | n.d. | 16.3 | ARDS | 100 | 100 | ||||
Shih, 1997* | Prospective | 13 vs 5 | MAA in serum | Not stated | 53.8 ± 6.6 SEM | 9.0 ± 3.1 SEM | ng/mL | <0.05 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Backer, 1997* | Prospective | 43 vs 9 | AVLAC | Not stated | 0.20 ± 0.230 SD | 0.139 ± 0.176 SD | mEq/L | <0.001 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Lung biomarkers
Study | Design | No. of ALI/ARDS vs CPE | Marker | Timing of measurement | Mean value ± SD/SEM or median (IQR or range) in ALI/ARDS | Mean value ± SD/SEM or median (IQR or range) in CPE | Unit |
p value | AUC | 95% CI | Cutoff | For | Specificity (%) | Sensitivity (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Markers of airway epithelium injury | ||||||||||||||
Katayama, 2010* | Prospective | 21 vs 11 | Laminin gannma2 in ELF | Not stated | 6034 ± 6245 SD | 1237 ± 807 SD | ng/mL | <0.02 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Laminin gannma2 in plasma | 147 ± 83 SD | 35 ± 14 SD | ng/mL | <0.0001 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ||||
Kropski, 2009* | Prospective | 23 vs 9 | CCP 16 in PEF | Within 24 h of diagnosis | 1950 (IQR1780–4024) | 4835 (IQR2006–6350) | ng/mL | 0.044 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
CCP 16 in serum | 22 (IQR9–44) | 55 (IQR18–123) | ng/mL | 0.053 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ||||
Chandel, 2009* | Prospective | 15 vs 5 | KGF in BAL | Within 48 h after intubation | 1.2-fold ±0.12 SD | 2.4-fold ±0.48 SD | fold | <0.01 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Newman, 2000* | Prospective | 15 vs 12 | HTI56 in PEF | Within 15 min after intubation | 1451 ± 6 727 | 335 ± 123 | ug/mL | <0.0001 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
HTI56 in plasma | 217 ± 79 | 335 ± 123 | ug/mL | <0.05 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ||||
Shimura,1996* | Prospective | 5 vs 11 | SP-A in sputum | Not stated | 311 ± 47 SEM | 1324 ± 197 SEM | ug/mL | <0.001 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Gunther, 1996* | Prospective | 15 vs 13 | SP-A in BAL | Within 72 h after intubation | 849 ± 96 SEM | 1013 ± 111 SEM | ng/mL | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
SP-B in BAL | 867 ± 131 SEM | 628 ± 42 SEM | ng/mL | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ||||
Protein ratio of fluid to plasma | ||||||||||||||
Ware, 2010*** | Prospective | 209 vs 147 | Fluid-to-plasma protein ratio | Not stated | 0.89 ± 0.36 SD | 0.53 ± 0.21 SD | n.d. | <0.001 | 0.84 | 0.79-0.88 | 0.65 | ALI/ARDS | 81 | 81 |
Colucci, 2009* | Prospective | 18 vs 9 | Protein ratio of fluid by s-Cath to plasma | Within 1–4 h after intubation | Prim. 0.32 ± 0.42 SD, Sec. 0.81 ± 0.33 SD | 0.20 ± 0.19 SD | n.d. | 0.002 in Sec. vs CPE | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Schutte, 1996* | Prospective | 12 vs 6 | Protein in BAL | Within 72 h after intubation | 671 ± 256 SEM | 291 ± 81 SEM | ug/mL | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
PMN in BAL | 16.1 ± 5.8 SEM | 0.4 ± 0.11 × 10^6 | /mL | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ||||
Serum CRP* | 235 ± 33 SEM | 93 ± 25 SEM | mg/L | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ||||
Miller, 1996* | Prospective | 27 vs 8 | Protein in PEF/plasma | Within 30 min after intubation | 0.90 ± 0.09 SEM in w/o sepsis, 0.84 ± 0.16 SEM in w sepsis, | 0.48 ± 0.12 SEM | Ratio | <0.05 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
Others | ||||||||||||||
Kushimoto, 2012*** | Prospective | 207 vs 26 | EVWI | Not stated | 18.5 ± 6.8 SD | 14.4 ± 4.0 SD | mL/kg | <0.01 | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. |
PVPI | 3.2 ± 1.4 SD | 2.0 ± 0.8 SD | n.d. | <0.01 | 0.886 | 0.836-0.953 | 2.6–2.85 | ALI/ARDS | 0.9 | 0.95 |
Imaging studies
Study | Design | No. of ALI/ARDS vs CPE | Marker | Timing of measurement | AUC | 95% CI | Cutoff | For | Specificity (%) | Sensitivity (%) |
---|---|---|---|---|---|---|---|---|---|---|
Sekiguchi, 2015*** | Prospective | 42 vs 59 | Combined cardiac and thoracic ultrasonography | Within 6 h of diagnosis | ||||||
Number of chest zones with positive B-lines | 0.82 | 0.75–0.88 | 3 | Miscellaneous causes | 42 (95% CI 32–52) | 100 (95% CI 89–100) | ||||
Score; left pleural effusion >20 mm (+4), Moderate or severe LV dysfunction (+3), and IVC minimal diameter < =23 mm (-2). | 0.79 | 0.70–0.87 | > = 6 | CPE | 98 (95% CI 87–100) | 39 (95% CI 26–52) | ||||
Komiya, 2013** | Retrospective | 20 vs 41 | Chest CT | Within 2 hours of arrival at ED | ||||||
Upper-lobe-predominant GGA | CPE | 95 | 48.8 | |||||||
Central-predominant GGA | CPE | 90 | 58.5 | |||||||
Central airspace consolidation | CPE | 90 | 56.1 | |||||||
Small ill-defined opacities | ARDS | 87.8 | 35 | |||||||
Left-dominant pleural effusion | ARDS | 95.1 | 25 | |||||||
Copetti, 2008** | Prospective | 18 vs 40 | Chest sonography | Not stated | ||||||
Alveolar-interstitial syndrome | ALI/ARDS | 0 | 100 | |||||||
CPE | 0 | 100 | ||||||||
Pleural line abnormalities | ALI/ARDS | 45 | 100 | |||||||
CPE | 0 | 25 | ||||||||
Reduction or absence of lung sliding | ALI/ARDS | 100 | 100 | |||||||
CPE | 0 | 0 | ||||||||
Spared areas | ALI/ARDS | 100 | 100 | |||||||
CPE | 0 | 0 | ||||||||
Consolidations | ALI/ARDS | 100 | 83.3 | |||||||
CPE | 0 | 0 | ||||||||
Pleural effusion | ALI/ARDS | 5 | 66.6 | |||||||
CPE | 33.3 | 95 | ||||||||
Lung pulse | ALI/ARDS | 100 | 50 | |||||||
CPE | 50 | 0 |